• Female patients aged 18 to 75 years inclusive

• Patients with non-metastatic breast cancer for whom adjuvant hormone therapy (anti-oestrogen or anti-aromatase) is indicated, depending on the decision of the multidisciplinary consultation meeting.

• Performance status (ECOG) ≤ 2

• Patient able to read and understand French (common use)

• Patient with access to an internet connection (for collection of adverse events and responses to questionnaires on the electronic platform)

• Patient who has been informed and has given written consent to participate in the study

• Patient affiliated to the French social security system or equivalent